Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 518

1.

Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.

Hurria A, Wong FL, Pal S, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A.

Oncologist. 2009 Sep;14(9):883-90. doi: 10.1634/theoncologist.2009-0056. Epub 2009 Sep 2.

2.

Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.

Naeim A, Wong FL, Pal SK, Hurria A.

Clin Breast Cancer. 2010 Apr;10(2):136-43. doi: 10.3816/CBC.2010.n.018.

3.

Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A.

J Clin Oncol. 2008 Nov 20;26(33):5386-92. doi: 10.1200/JCO.2008.17.6891. Epub 2008 Oct 27.

4.

Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.

Hurria A, Naeim A, Elkin E, Limaye S, Grover A, Hudis C, Pearce C, Robson M.

Crit Rev Oncol Hematol. 2007 Mar;61(3):255-60. Epub 2006 Nov 13.

PMID:
17098441
5.

The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer.

Ring A.

Crit Rev Oncol Hematol. 2010 Nov;76(2):127-32. doi: 10.1016/j.critrevonc.2010.01.002. Epub 2010 Jan 22.

PMID:
20097087
6.

Acceptance of adjuvant chemotherapy recommendations in early-stage hormone-positive breast cancer.

Marcinkowski EF, Ottesen R, Niland J, Vito C.

J Surg Res. 2017 Jun 15;214:79-85. doi: 10.1016/j.jss.2017.02.035. Epub 2017 Feb 28.

PMID:
28624063
7.

Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit.

Whitfield R, Kollias J, De Silva P, Zorbas H, Maddern G.

ANZ J Surg. 2012 Apr;82(4):234-9. doi: 10.1111/j.1445-2197.2011.05998.x. Epub 2012 Jan 15.

PMID:
22510180
8.

Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).

Biganzoli L, Goldhirsch A, Straehle C, Castiglione-Gertsch M, Therasse P, Aapro M, Minisini A, Piccart MJ; BIG.

Ann Oncol. 2004 Feb;15(2):207-10.

PMID:
14760110
9.

Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?

Skedgel C, Rayson D, Younis T.

Ann Oncol. 2013 Jul;24(7):1834-40. doi: 10.1093/annonc/mdt069. Epub 2013 Mar 19.

PMID:
23510987
10.

Treatment recommendations for older women with breast cancer: A survey among surgical, radiation and medical oncologists.

Hamelinck VC, Stiggelbout AM, van de Velde CJH, Liefers GJ, Bastiaannet E.

Eur J Surg Oncol. 2017 Jul;43(7):1288-1296. doi: 10.1016/j.ejso.2017.02.006. Epub 2017 Feb 20.

PMID:
28258786
11.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

12.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

13.

Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.

Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G.

Oncologist. 2008 Apr;13(4):361-9. doi: 10.1634/theoncologist.2007-0207.

14.

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.

Paluch-Shimon S, Wolf I, Goldberg H, Evron E, Papa MZ, Shabtai M, Barsuk D, Yosepovich A, Modiano T, Catane R, Kaufman B.

Acta Oncol. 2008;47(8):1564-9. doi: 10.1080/02841860802060844.

PMID:
18607846
15.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

16.

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D.

Breast Cancer Res Treat. 2007 Mar;101(3):355-65. Epub 2006 Jul 19.

PMID:
16850247
17.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
18.

Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting.

Hawfield A, Lovato J, Covington D, Kimmick G.

Crit Rev Oncol Hematol. 2006 Sep;59(3):250-5. Epub 2006 Mar 9.

PMID:
16527489
19.

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.

McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.

Cancer. 2011 Dec 15;117(24):5461-8. doi: 10.1002/cncr.26171. Epub 2011 Jun 16.

20.

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.

Nabholtz JM, Gligorov J.

Expert Opin Pharmacother. 2005 Aug;6(9):1555-64. Review.

PMID:
16086643

Supplemental Content

Support Center